GS
The Goldman Sachs Group, Inc.
GS's fundamentals are strong: revenue grew 19% and its operating margin rose 4 points to 40%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
HIVE
HIVE Digital Technologies Ltd.
There isn't enough reported data to score HIVE yet.
GS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| N/A | |
| N/A |
GS's revenue and profitability are currently strong. Free cash flow and net leverage aren't meaningful measures for financial services companies like GS.
HIVE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| N/A | |
| N/A |
HIVE's revenue is currently healthy, but its profitability is weak. Free cash flow and net leverage aren't meaningful measures for financial services companies like HIVE.
GS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.6x | $528 | -42% |
| Current | 13x | $914 | — |
| Forward | 13x | $914 | — |
| Fair | 14x | $940 | +2.9% |
| Expensive | 17x | $1,214 | +33% |
Historical ranges are pointers, not guarantees.
GS's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
HIVE PE Valuation
HIVE has no meaningful PE right now: it lost money over the past year.
GS Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for GS, with profitability improving. However, they disagree widely on these estimates.
HIVE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect HIVE's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
GS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $72.35 | +4% |
| Q3 2026 | $69.58 | +41% |
| Q2 2026 | $64.82 | +43% |
| Q1 2026 | $54.75 | +27% |
| Q4 2025 | $51.32 | +27% |
| Q3 2025 | $49.22 | +44% |
| Q2 2025 | $45.37 | +45% |
| Q1 2025 | $43.08 | +68% |
| Q4 2024 | $40.54 | +77% |
GS has the edge over HIVE on earnings quality, reporting a profit while its opponent remains loss making.
HIVE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.60 | -1433% |
| Q2 2026 | -$1.38 | -1162% |
| Q1 2026 | -$0.66 | -$0.44 |
| Q4 2025 | -$0.27 | -154% |
| Q3 2025 | $0.12 | -71% |
| Q2 2025 | $0.13 | -28% |
| Q1 2025 | -$0.22 | -238% |
| Q4 2024 | $0.50 | +$0.98 |
HIVE has swung to a loss: it lost $1.60 per share over the past year, after a profit the year before.
GS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $18.7B | +23% |
| Q2 2026 | $20.3B | +39% |
| Q1 2026 | $17.2B | +14% |
| Q4 2025 | $13.5B | -3% |
| Q3 2025 | $15.2B | +20% |
| Q2 2025 | $14.6B | +15% |
| Q1 2025 | $15.1B | +6% |
| Q4 2024 | $13.9B | +23% |
GS's revenue is growing: $18.7B last quarter, up 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 37% | +2 points |
| Q2 2026 | 42% | +8.1 points |
| Q1 2026 | 38% | +0.2 points |
| Q4 2025 | 44% | +5.6 points |
| Q3 2025 | 36% | +4.1 points |
| Q2 2025 | 34% | +3.2 points |
| Q1 2025 | 37% | +0.6 points |
| Q4 2024 | 38% | +18 points |
GS's operating margin was 37% last quarter, up 2 points from the same quarter a year ago.
HIVE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $84.9M | -2.7% |
| Q2 2026 | $79.1M | +73% |
| Q1 2026 | $71.8M | +130% |
| Q4 2025 | $93.1M | +219% |
| Q3 2025 | $87.3M | +285% |
| Q2 2025 | $45.6M | +41% |
| Q1 2025 | $31.2M | -16% |
| Q4 2024 | $29.2M | -6.5% |
HIVE's revenue is growing: $85M last quarter, down 2.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -227% | -232 points |
| Q4 2025 | 18% | +25 points |
| Q3 2025 | -11% | +9.1 points |
| Q2 2025 | 78% | +132 points |
| Q1 2025 | 5.2% | -84 points |
| Q4 2024 | -7% | -30 points |
| Q3 2024 | -20% | -6.7 points |
| Q2 2024 | -54% | -68 points |
HIVE's operating margin was −227% last quarter, down 232 points from the same quarter a year ago, near the bottom of its range since 2019.
GS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +72% |
| Q2 2026 | $5.6B | +7.8% |
| Q1 2026 | -$32.4B | +$5.3B |
| Q4 2025 | -$16.8B | -136% |
| Q3 2025 | $2.1B | +$40.6B |
| Q2 2025 | $5.2B | -6.8% |
| Q1 2025 | -$37.7B | -$9.2B |
| Q4 2024 | $46.2B | +$75.1B |
GS's free cash flow was −$40B over the past year, against $15.8B the year before. Free cash flow isn't a meaningful measure for financial services companies like GS.
HIVE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $858K | +$49.1M |
| Q2 2026 | -$10.7M | +$26.4M |
| Q1 2026 | -$21.8M | +$7.8M |
| Q4 2025 | -$9M | +$80.9M |
| Q3 2025 | -$48.2M | -$26.2M |
| Q2 2025 | -$37.1M | -$19.4M |
| Q1 2025 | -$29.5M | +$8.3M |
| Q4 2024 | -$89.9M | -$63.8M |
HIVE's free cash flow was −$41M over the past year, against −$205M the year before. Free cash flow isn't a meaningful measure for financial services companies like HIVE.
GS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -3.8M shares |
| 1 year | -4.4% | -13.9M shares |
| 3 years | -12% | -42.8M shares |
| 5 years | -15% | -52.8M shares |
| Available history | -20% | -74.4M shares |
GS has the edge over HIVE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3B |
| Q2 2026 | $4B |
| Q1 2026 | $5B |
| Q4 2025 | $3B |
| Q3 2025 | $2B |
| Q2 2025 | $3B |
| Q1 2025 | $4.4B |
| Q4 2024 | $2B |
GS spent $15B buying back its own shares over the past year, up 32% from the year before.
HIVE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.9% | +7.8M shares |
| 1 year | +20% | +45.9M shares |
| 3 years | +222% | +189M shares |
| 5 years | +242% | +194M shares |
| Available history | +319% | +209M shares |
HIVE has 274M diluted shares, up 20% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
GS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -5.4x | Net Cash |
| Q2 2026 | -6.1x | Net Cash |
| Q1 2026 | -6.7x | Net Cash |
| Q4 2025 | -6.4x | Net Cash |
| Q3 2025 | -3.5x | Net Cash |
| Q2 2025 | -3.1x | Net Cash |
| Q1 2025 | -3.9x | Net Cash |
| Q4 2024 | -4.7x | Net Cash |
GS has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like GS.
HIVE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 1.8x | Healthy |
| Q4 2025 | 0.0x | Very low |
| Q3 2025 | 0.0x | Very low |
| Q2 2025 | 0.3x | Very low |
| Q1 2025 | 4.1x | High |
| Q4 2024 | 0.2x | Very low |
| Q3 2024 | 0.3x | Very low |
| Q2 2024 | 0.0x | Very low |
HIVE's net debt is about 1.8 years of its operating earnings (EBITDA), down from 4.1 years a year ago. Net leverage isn't a meaningful measure for financial services companies like HIVE.
GS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.5 | Neutral |
| Stochastic | 16.3 | Oversold |
GS's weekly RSI is 45 (neutral) and its Stochastic is 16 (oversold).
HIVE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.7 | Neutral |
| Stochastic | 6.1 | Oversold |
HIVE's weekly RSI is 35 (neutral) and its Stochastic is 6 (oversold).
GS PE vs Financial Services Sector
| Metric | GS | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 13x | 0.8% above |
| PE % | 46 | 63 | 17 pts below |
GS is trading at 13x earnings, in line with the Financial Services sector's median of 13x, though its earnings don't support one.
HIVE PE vs Financial Services Sector
| Metric | HIVE | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
HIVE has no meaningful PE right now: it lost money over the past year.
GS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $895.5 | 2% above |
| 20 week MA | $977.4 | 6.5% below |
| 50 week MA | $945.4 | 3.4% below |
| 100 week MA | $804.5 | 14% above |
| 200 week MA | $602.7 | 52% above |
GS has the edge over HIVE on trend strength, trading above more of its moving averages.
HIVE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.24 | 26% below |
| 20 week MA | $2.70 | 39% below |
| 50 week MA | $2.79 | 41% below |
| 100 week MA | $2.78 | 41% below |
| 200 week MA | $3.12 | 47% below |
HIVE is in a downtrend: it's below all five of its weekly moving averages, and 47% below its 200-week average.
GS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $230.7 | $256.2 | +11% |
| 2021 | $256.2 | $385.0 | +50% |
| 2022 | $385.0 | $345.5 | -10% |
| 2023 | $345.5 | $385.8 | +12% |
| 2024 | $385.8 | $576.2 | +49% |
| 2025 | $576.2 | $907.0 | +57% |
| 2026 YTD | $907.0 | $913.6 | +0.7% |
GS has the edge over HIVE on returns for 2026, with the stronger performance.
HIVE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $0.40 | $8.30 | +1975% |
| 2021 | $8.30 | $15.3 | +84% |
| 2022 | $15.3 | $1.59 | -90% |
| 2023 | $1.59 | $4.53 | +185% |
| 2024 | $4.53 | $2.97 | -34% |
| 2025 | $2.97 | $2.72 | -8.4% |
| 2026 YTD | $2.72 | $1.65 | -39% |
HIVE's yearly returns have swung widely, from +1975% in 2020 to −90% in 2022. It's down 39% so far in 2026.